Group 1 - Biophytis has confirmed the launch of the Phase 2 OBA clinical trial in obesity, expected to begin as early as possible in 2025 [1] - The company recently announced a €2.6 million capital increase and will continue the clinical development of BIO101 in obesity, aiming to evaluate its efficacy and safety in reducing muscle strength loss caused by GLP-1 agonists in patients with obesity [2] - Biophytis received Investigational New Drug (IND) clearance from the FDA in July 2024, marking a significant milestone for the OBA program [3] Group 2 - The CEO of Biophytis stated that the company's priority is to find a pharmaceutical partner to co-develop BIO101 in obesity, which will support clinical and regulatory development through to marketing authorization [4] - Biophytis SA is focused on developing drug candidates for age-related diseases, with BIO101 being its lead drug candidate targeting muscular diseases, respiratory diseases, and metabolic disorders [4]
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity